

СООБЩЕНИЕ

о результатах осуществления прав голоса по акциям, составляющим не менее пяти процентов стоимости активов  
Открытого паевого инвестиционного фонда рыночных финансовых инструментов «БСПБ – Глобальный»

Полное наименование общества	Сокращенное наименование общества	Дата проведения ОСА	Формулировка вопроса в повестке дня ОСА	Формулировка принятого решения	Сведения о том, голосовала ли УК
CASI Pharmaceuticals, Inc.	CASI Pharmaceuticals, Inc.	20.06.2019	<p>1. To elect two directors;</p> <p>2. To approve an amendment to our 2011 Long-Term Incentive Plan increasing the number of shares of Common Stock reserved for issuance from 20,230,000 to 25,230,000;</p> <p>3. To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 170,000,000 to 250,000,000;</p> <p>4. To approve the issuance of equity compensation to the Chairman and CEO pursuant to Nasdaq Listing Rule Section 5635(c) and, if applicable, Nasdaq Listing Rule Section 5635(b);</p> <p>5. To ratify the appointment of KPMG Huazhen LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;</p> <p>6. To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.</p>	<p>CASI Pharmaceuticals, Inc. (the "Company") held its 2019 annual meeting of stockholders (the "Annual Meeting") on June 20, 2019. At the Annual Meeting, the Company's stockholders approved an amendment to the Company's 2011 Long-Term Incentive Plan (the "2011 Plan").</p> <p>Under the amendment to the 2011 Plan, the number of shares of Common Stock reserved for issuance increased from 20,230,000 to 25,230,000. The Company's executive officers and directors are eligible to receive awards under the 2011 Plan in accordance with the terms and conditions set forth therein. A copy of the 2011 Plan was filed with the Securities and Exchange Commission on April 30, 2019 as Appendix A to the Company's Definitive Proxy Statement on Schedule 14A (the "Proxy Statement") for the Annual Meeting and is incorporated herein by reference.</p> <p>Item 5.07. Submission of Matters to a Vote of Security Holders.</p> <p>At the Annual Meeting, the Company's stockholders considered and approved five proposals, each of which is described in more detail in the Proxy Statement. The following is a brief description of each matter voted upon at the Annual Meeting, and the final voting results for each matter, including the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter.</p> <p>Election of Directors. Each of James Huang and Quan Zhou, Ph.D. were elected to serve as a member of the Board of Directors for a term expiring at the annual meeting of stockholders as indicated in the Proxy Statement and until his successor is duly elected and qualified, as follows:</p> <p>Director FOR WITHHELD BROKER NON-VOTES James Huang 55,909,826 2,390,148 21,645,261 Quan Zhou, Ph.D. 58,032,603 267,371 21,645,261</p> <p>Approval of an amendment to the 2011 Long-Term Incentive Plan. The stockholders voted to approve the amendments to the 2011 Plan, as follows: FOR 55,279,180 AGAINST 2,990,611 ABSTAIN 30,183 BROKER NON-VOTES 21,645,261</p> <p>Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 170,000,000 to 250,000,000. The stockholders voted to approve the amendment to the Amended and Restated Certificate of Incorporation as follows: FOR 75,977,345 AGAINST 2,445,315 ABSTAIN 253,672 BROKER NON-VOTES 1,268,903</p> <p>Approval of the issuance of equity compensation to the Company's Chairman and CEO. The stockholders voted to approve the issuance of option grants to the Chairman and CEO pursuant to Nasdaq Listing Rule 5635(c) and, if applicable, Nasdaq Listing Rule 5635(b), as follows: FOR 55,154,360 AGAINST 3,110,443 ABSTAIN 35,171 BROKER NON-VOTES 21,645,261</p> <p>Ratification of Independent Registered Public Accountants. The stockholders voted to ratify the appointment of KPMG Huazhen LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019, as follows: FOR 79,525,019 AGAINST 320,559 ABSTAIN 99,657 BROKER NON-VOTES 0</p>	НЕ ГОЛОСОВАЛА

Генеральный директор



Д.В. Шагардин